Quick Answer
Moleculin Biotech, Inc. reported Cash And Cash Equivalents At Carrying Value of $8.88 million for the year ending 2025.
- Moleculin Biotech, Inc. showed an increase of +107.5% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Moleculin Biotech, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2015 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2015: $87.3 thousand | Q1 2016: $260.0 thousand | Q2 2016: $7.25 million | Q3 2016: $6.18 million | Q1 2017: $8.88 million | Q2 2017: $9.27 million | Q3 2017: $8.74 million | Q1 2018: $13.11 million | Q2 2018: $11.72 million | Q3 2018: $8.60 million | Q1 2019: $8.78 million | Q2 2019: $18.70 million | Q3 2019: $15.41 million | Q1 2020: $11.65 million | Q2 2020: $16.73 million | Q3 2020: $12.80 million | Q1 2021: $86.29 million | Q2 2021: $79.51 million | Q3 2021: $75.18 million | Q1 2022: $66.10 million | Q2 2022: $58.00 million | Q3 2022: $50.39 million | Q1 2023: $37.27 million | Q2 2023: $32.17 million | Q3 2023: $24.58 million | Q1 2024: $16.82 million | Q2 2024: $10.85 million | Q3 2024: $9.41 million | Q1 2025: $7.72 million | Q2 2025: $7.56 million | Q3 2025: $6.70 million.
- Historical annual values: Fiscal year 2025: $8.88 million | Fiscal year 2024: $4.28 million | Fiscal year 2023: $23.55 million | Fiscal year 2022: $43.15 million | Fiscal year 2021: $70.90 million | Fiscal year 2020: $15.17 million | Fiscal year 2019: $10.74 million | Fiscal year 2018: $7.13 million | Fiscal year 2017: $7.71 million | Fiscal year 2016: $5.01 million | Fiscal year 2015: $28.0 thousand | Fiscal year 2015: $0.00.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: